SLC16A1 and cancer: Due to the already referred role in cancer, MCT1 inhibition (Figure 2) stands as a therapeutic solution, and studies on this molecule as a therapeutic target revealed that its blockade improves therapy response and survival chances both in vitro and in vivo.